Literature DB >> 8178624

Prognostic value of cerebrospinal fluid neuron-specific enolase and S-100b protein in Guillain-Barré syndrome.

K Mokuno1, K Kiyosawa, K Sugimura, T Yasuda, S Riku, T Murayama, T Yanagi, A Takahashi, K Kato.   

Abstract

We measured the cerebrospinal fluid (CSF) concentrations of neuron-specific enolase (NSE) and S-100b protein (S-100b) using enzyme immunoassay methods, in 24 patients with Guillain-Barré syndrome and 46 controls, and examined their prognostic values. Sixteen of 24 patients showed elevated levels (> the mean + 2SD levels of controls) of NSE, S-100b, or both, and in those with higher NSE or S-100b levels there was a rather longer duration of disease, whereas 8 patients with the normal levels showed an early recovery. Further, NSE or S-100b levels were significantly correlated with months to recovery. Thus, NSE and S-100b in CSF may be useful markers for predicting the outcome of Guillain-Barré syndrome.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8178624

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  12 in total

Review 1.  Guillain-Barré syndrome.

Authors:  U Seneviratne
Journal:  Postgrad Med J       Date:  2000-12       Impact factor: 2.401

2.  Clinico-pathophysiological features of acute autonomic and sensory neuropathy: a long-term follow-up study.

Authors:  T Yasuda; G Sobue; K Mokuno; S Hakusui; T Ito; Y Hirose; T Yanagi
Journal:  J Neurol       Date:  1995-10       Impact factor: 4.849

3.  Elevated levels of S100B, tau and pNFH in cerebrospinal fluid are correlated with subtypes of Guillain-Barré syndrome.

Authors:  Xiao-Ke Wang; Hong-Liang Zhang; Fan-Hua Meng; Ming Chang; Yu-Zhi Wang; Tao Jin; Eilhard Mix; Jie Zhu
Journal:  Neurol Sci       Date:  2012-04-22       Impact factor: 3.307

4.  High-resolution nuclear magnetic resonance spectroscopic study of metabolites in the cerebrospinal fluid of patients with cervical myelopathy and lumbar radiculopathy.

Authors:  Hideki Nagashima; Yasuo Morio; Shunsuke Meshitsuka; Koji Yamane; Yoshiro Nanjo; Ryota Teshima
Journal:  Eur Spine J       Date:  2010-05-20       Impact factor: 3.134

Review 5.  Cerebrospinal fluid biomarkers in Guillain-Barré syndrome--where do we stand?

Authors:  Johannes Brettschneider; Axel Petzold; Sigurd Süssmuth; Hayrettin Tumani
Journal:  J Neurol       Date:  2009-02-16       Impact factor: 4.849

6.  Tumor necrosis factor-alpha, interleukin-1beta, and interleukin-6 in the cerebrospinal fluid of patients with cervical myelopathy and lumbar radiculopathy.

Authors:  Hideki Nagashima; Yasuo Morio; Koji Yamane; Yoshiro Nanjo; Ryota Teshima
Journal:  Eur Spine J       Date:  2009-06-19       Impact factor: 3.134

7.  Cerebrospinal fluid S-100 protein levels in neurological pathologies.

Authors:  J R Infante; A Martínez; J Ochoa; F Cañadillas; M Torres-Avisbal; J A Vallejo; F M González; C Pacheco; J M Latre
Journal:  J Physiol Biochem       Date:  2003-12       Impact factor: 4.158

Review 8.  Clinical significance of serum biomarkers in pediatric solid mediastinal and abdominal tumors.

Authors:  John A Sandoval; Linda H Malkas; Robert J Hickey
Journal:  Int J Mol Sci       Date:  2012-01-20       Impact factor: 6.208

9.  Identification of gene networks and pathways associated with Guillain-Barré syndrome.

Authors:  Kuo-Hsuan Chang; Tzi-Jung Chuang; Rong-Kuo Lyu; Long-Sun Ro; Yih-Ru Wu; Hong-Shiu Chang; Chin-Chang Huang; Hung-Chou Kuo; Wen-Chuin Hsu; Chun-Che Chu; Chiung-Mei Chen
Journal:  PLoS One       Date:  2012-01-10       Impact factor: 3.240

10.  Alpha-enolase involvement in intestinal and extraintestinal manifestations of celiac disease.

Authors:  Aaron Lerner; Polina Sobolevskaia; Leonid Churilov; Yehuda Shoenfeld
Journal:  J Transl Autoimmun       Date:  2021-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.